Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.

BACKGROUND We conducted this study to estimate the prevalence of biomarkers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) among patients with breast cancer and to explore their effects on disease mortality. METHODS We conducted this registry-based retrospective cohort study in Tehran, in 2014, using the data on 1622 patients with breast cancer, diagnosed pathologically and registered with the Comprehensive Cancer Control Center from 1998 to 2013. The outcome of interest was the survival probability of patients with breast cancer based on receptor status along with other prognostic factors such as age, histopathology, stage/grade of tumor, metastatic status, and surgical procedures using the life table, Kaplan-Meier curves, and multivariate Cox proportional hazard model. We generated different subtypes based on expression of ER, PR, and HER2, positive (+) and/or negative (-). RESULTS ER+/PR+/HER2- subtype (51.5%) was the most common form of breast cancer cells. Compared to the ER+/PR+/HER- subtype, the hazard ratio (95% confidence interval) of cancer mortality was 2.14 (1.13, 4.03) for ER-/PR-/HER2- subtype, 1.92 (1.03, 3.59) for ER-/PR-/HER2+ subtype and 5.19 (1.51, 17.86) for ER-/PR+/HER2+ subtype. CONCLUSION In this study, breast cancer cases with ER-/HER2+ tumors had shorter survival than those with ER+/PR+/HER2- tumors. Triple negative tumors were the only other subtype with a statistically significant poorer prognosis. The results of this study in a middle-income country further indicate the importance of receptor status, in particular HER2 status, in the prognosis of breast cancer.

[1]  B. Mellado,et al.  Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Poorolajal,et al.  Effect of Body Mass Index on Breast Cancer during Premenopausal and Postmenopausal Periods: A Meta-Analysis , 2012, PloS one.

[3]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[4]  Maznah Dahlui,et al.  Breast cancer prevention and control programs in Malaysia. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[5]  A. Harris,et al.  HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer , 2010, PLoS biology.

[6]  S. Ménard,et al.  HER2 as a Prognostic Factor in Breast Cancer , 2001, Oncology.

[7]  W. Woodward,et al.  Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer , 2009, The American journal of surgical pathology.

[8]  Maryam Farhadian,et al.  Predicting 5-Year Survival Status of Patients with Breast Cancer based on Supervised Wavelet Method , 2014, Osong public health and research perspectives.

[9]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[10]  E. Tokunaga,et al.  High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers , 2012, Breast Cancer.

[11]  E. van Limbergen,et al.  Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Schoenbach,et al.  The potential and limitations of data from population-based state cancer registries. , 2000, American journal of public health.

[13]  M. Aghili,et al.  Triple-negative breast cancer survival in Iranian patients. , 2013, Acta medica Iranica.

[14]  C. Yip,et al.  The estrogen receptor negative-progesterone receptor positive breast carcinoma is a biological entity and not a technical artifact. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[15]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[17]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[18]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Shak.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. , 1999, Seminars in oncology.